10/9/2008

Watson Pharmaceuticals secured FDA approval for Rapaflo, a once-daily treatment for symptoms of prostate enlargement, including urinary resistance and pain. The drug, which Watson licensed from Kissei Pharmaceutical in 2004, could generate $34.8 million in sales by 2010, an analyst said.

Full Story:
Bloomberg

Related Summaries